Navigation Links
Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/6/2009

2009 2008 ASSETS Current Assets: Cash and cash equivalents $57,005 $76,315 Short-term investments (including restricted investments) 1,067 2,282 Accounts receivable, net 727 822 Inventories, net 1,507 1,892 Recoverable income taxes 5,526 5,526 Prepaid expenses and other current assets 2,275 2,782 Total current assets 68,107 89,619 Deferred income taxes, net 4,500 4,200 Property and equipment, net 1,273 1,393 Other assets (including restricted cash and investments) 3,103 3,010 Total assets $76,983 $98,222 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $5,636 $5,888 Deferred revenues 371 451 Other current liabilities 16,652 18,650 Total current liabilities 22,659 24,989 Other liabilities 10,230 9,809 Commitments and contingencies Stockholders' Equity: Preferred stock - $.01 par value 4,000,000 shares authorized; no shares issued - - Common stock - $.01 par value 150,000,000 shares authorized; 54,960,000 issued and outstanding at March 31, 2009 and 54,654,000 shares issued and outstanding at December 31, 2008
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Announces Appointment of David Gionco as Chief Financial Officer
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
8. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 ReliantHeart, Inc., an innovative ... a supplier of precision transit-time flow measurement solutions, are ... improve the efficiency of the HeartAssist5® Left ... to experience greater mobility and peace of mind. ... flow board, will draw 1/6th of the power required ...
(Date:3/25/2015)... (PRWEB) March 26, 2015 Agnition announced ... episode of American Farmer, airing for the first time ... segment of American Farmer will explore the extremely important ... crop producers with a patented Microbial Catalyst™ technology that ... greater yields. The segment will air again on April ...
(Date:3/25/2015)... 2015 Laboratory workers can turn ... Analytical Balances to get best-performing features while still ... balances from the trusted brand include: , ... your efficiency by providing a large weighing surface ... modes include parts counting, percent weighing, checkweighing, animal/dynamic ...
(Date:3/25/2015)... March 25, 2015 Data from ... Mechanism of Action in Neuromuscular Diseases , ... Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication of ... troponin activator tirasemtiv in the journal Neurotherapeutics. ... “Evidence of Effect” or hypothesis-generating clinical trial which ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... Tekturna HCT combines first approved direct renin inhibitor with the ... - Data show combination of Tekturna and HCTZ resulted in significant ... patients are not at goal and most require two or more, ... ...
... CHICAGO, Jan. 18 Brinks Hofer Gilson & ... the United States, is,pleased to announce that 21 of ... in a survey conducted by Law & Politics magazine.,Additionally, ... Meredith Martin Addy, chair of the Appellate Group ...
... 18 Abbott (NYSE: ABT ),announced today it ... its fully automated HTLV-I/HTLV-II blood screening test,for use on ... use by,laboratories to screen individual donations of blood and ... I and/or human T --,lymphotropic virus Type II (anti-HTLV-I/HTLV-II)., ...
Cached Biology Technology:Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 2Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 3Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 4Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 5Twenty-One Brinks Hofer Gilson & Lione Attorneys Named 2008 'Illinois Super Lawyers' 2Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II 2Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II 3
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... , March 17, 2015 Emotient, the ... software, today announced general availability of Emotient ... for the analysis of facial expressions. The system ... media content, products and services. It delivers audience ... and sentiment - as derived from facial evidence ...
(Date:3/12/2015)... WINSTON-SALEM, N.C. , March 12, 2015 ... afternoon at Brenner Children,s Hospital, part of Wake Forest ... an outreach initiative for the 2015 ACC Men,s Basketball ... taking pictures with them and getting their autographs. ... Wake Forest Baptist. It is the only children,s hospital ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... EUREKA project E! 3025 MONALISA has developed a new, completely ... as growth promoters and to prevent the damaging effects of ... have been prohibited for use in animal feed in the ... effective antimycotoxic agent. The already-known capacity of clay minerals to ...
... massive humpbacks glide through the sea with ease to the ... excavated the equations behind a variety of complex phenomena. ... working closely with a team of Harvard evolutionary biologists led ... icon of evolution: the beaks of Darwin,s finches. In ...
... Thanks to the introduction of various non-native species ... feral animals. A new application developed by ecologists at ... first issue of Methods in Ecology and Evolution ... aims to improve the success of wildlife managers tasked ...
Cached Biology News:French and Spanish researchers develop a natural alternative to antibiotics in animal feed 2French and Spanish researchers develop a natural alternative to antibiotics in animal feed 3Simple math explains dramatic beak shape variation in Darwin's finches 2Simple math explains dramatic beak shape variation in Darwin's finches 3Killing in the name of conservation 2
... EVO384R are fast multi-channel pipetting platforms consisting ... sizes, with a multi-channel head and a ... saving, with true parallel processing of sample ... assays with the Freedom EVOware program. ...
... General description: Aminopropylsilane ... commonly used slide chemistry ... APS Coated Slides for ... reliable glass substrate for ...
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
... (CYP450) metabolite postulated to play an autacoid ... In rat cerebral microvessels, 20-HETE is a ... is excreted mainly as the glucuronide conjugate. ... in human urine) is about 10-fold lower ...
Biology Products: